Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Samrat PharmachemBOM:530125 -0.04%63 Gross Margin % is 1.46% as of Mar. 2026, which is 79% below its 10-year median of 6.82. GuruFocus rates BOM:530125 with a GF Score™ of 63/100 and a GF Value™ of ₹362.79 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 1,558 Chemicals companies, Samrat Pharmachem ranks worse than 93.9% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Samrat Pharmachem had a gross margin of 1.46% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Samrat Pharmachem Gross Margin % Related Terms
Samrat Pharmachem Gross Margin % Historical Data
* Premium members only.
The historical data trend for Samrat Pharmachem's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Chemicals subindustry, Samrat Pharmachem's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Samrat Pharmachem Gross Margin % vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Samrat Pharmachem's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Samrat Pharmachem's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Samrat Pharmachem (BOM:530125) has a Gross Margin % of 1.46% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Samrat Pharmachem and its competitors. This is 79% below median its historical median of 6.82. Over the past decade, Samrat Pharmachem's Gross Margin % has ranged from 2.30 to 12.66. According to the industry distribution chart, Samrat Pharmachem ranks #1463 out of 1558 companies in the Chemicals industry, placing it in the top 93.9%.
Is Samrat Pharmachem's Gross Margin % too high?
Samrat Pharmachem's current Gross Margin % of 1.46% is 79% below median its 10-year median of 6.82. Over the past 10 years, this metric has ranged from a low of 2.30 to a high of 12.66. The Chemicals industry median Gross Margin % is 23.55. Samrat Pharmachem's value of 1.46% is 93.8% below this industry median. Based on the distribution chart, Samrat Pharmachem ranks #1463 out of 1558 companies in the Chemicals industry, which is in the bottom quartile relative to peers. Overall, Samrat Pharmachem has a GF Score™ of 63/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Samrat Pharmachem's Gross Margin % compare to DOW?
According to the Chemicals industry distribution chart, Samrat Pharmachem ranks #1463 out of 1558 companies for Gross Margin %. This places Samrat Pharmachem in the lower half of its industry. The industry median Gross Margin % is 23.55. Samrat Pharmachem's value of 1.46% is 93.8% below this benchmark. Historically, Samrat Pharmachem's own Gross Margin % has ranged from 2.30 to 12.66 over the past decade. While the company's 10-year median is 6.82 vs. the industry median of 23.55, Samrat Pharmachem has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Chemicals company?
The median Gross Margin % among Chemicals companies is 23.55, based on 1,558 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Samrat Pharmachem's current Gross Margin % of 1.46% is 93.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Samrat Pharmachem and its competitors. For the Chemicals industry, the median Gross Margin % is 23.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Samrat Pharmachem's current Gross Margin % is 1.46%, which is 79% below median its own 10-year median of 6.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Samrat Pharmachem stock overvalued right now?
Based on GuruFocus' analysis, Samrat Pharmachem (BOM:530125) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹362.79, compared to a current price of ₹247.85 — trading 31.7% below its estimated fair value. The current Gross Margin % is 1.46%, which is 79% below median its 10-year median of 6.82 and 93.8% below the Chemicals industry median of 23.55. Samrat Pharmachem's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Samrat Pharmachem (BOM:530125), the current Gross Margin % is 1.46% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Samrat Pharmachem (BOM:530125) Overvalued in 2026?
Based on GuruFocus' analysis, Samrat Pharmachem stock appears to be undervalued.
The current stock price of ₹247.85 is trading 31.7% below its estimated GF Value™ of ₹362.79.
GuruFocus considers Samrat Pharmachem to be Significantly Undervalued.
Key valuation signals for BOM:530125:
Gross Margin %: 1.46% (79% below median its 10-year median of 6.82)
GF Value™: ₹362.79 vs. price of ₹247.85 (31.7% below fair value)
Industry Position: 93.8% below the Chemicals median (#1463 of 1558)
No single metric tells the full story. See the BOM:530125 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Samrat Pharmachem Ltd is a producer of pharmaceutical chemicals. The principal activity of the company is to manufacture Iodine salts and bromine salts. Its product portfolio consists of potassium iodate, potassium iodide, methyl iodide, and copper iodide. Its products are used in various industries like pharmaceuticals and chemicals.
63GF Score
Get the complete analysis for BOM:530125
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530125 has been successfully added to your 
